Lilly pulling Lartruvo after failure in confirmatory study

Following the failure in January of Lartruvo olaratumab to show a survival benefit in a confirmatory study, Lilly now intends to withdraw the drug from the market. Since 2016, Lartruvo has been approved to

Read the full 341 word article

User Sign In